148 related articles for article (PubMed ID: 37558564)
1. Determination of "borderline resectable" pancreatic cancer - A global assessment of 30 shades of grey.
Badgery HE; Muhlen-Schulte T; Zalcberg JR; D'souza B; Gerstenmaier JF; Pickett C; Samra J; Croagh D;
HPB (Oxford); 2023 Nov; 25(11):1393-1401. PubMed ID: 37558564
[TBL] [Abstract][Full Text] [Related]
2. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
Lee DH; Ha HI; Jang JY; Lee JW; Choi JY; Bang S; Lee CH; Kim WB; Lee SS; Kim SC; Kang BK; Lee JM
Eur Radiol; 2023 Sep; 33(9):5965-5975. PubMed ID: 36988715
[TBL] [Abstract][Full Text] [Related]
3. Artificial intelligence for assessment of vascular involvement and tumor resectability on CT in patients with pancreatic cancer.
Bereska JI; Janssen BV; Nio CY; Kop MPM; Kazemier G; Busch OR; Struik F; Marquering HA; Stoker J; Besselink MG; Verpalen IM;
Eur Radiol Exp; 2024 Feb; 8(1):18. PubMed ID: 38342782
[TBL] [Abstract][Full Text] [Related]
4. Preoperative CT Classification of the Resectability of Pancreatic Cancer: Interobserver Agreement.
Joo I; Lee JM; Lee ES; Son JY; Lee DH; Ahn SJ; Chang W; Lee SM; Kang HJ; Yang HK
Radiology; 2019 Nov; 293(2):343-349. PubMed ID: 31502935
[TBL] [Abstract][Full Text] [Related]
5. Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial.
Wittel UA; Lubgan D; Ghadimi M; Belyaev O; Uhl W; Bechstein WO; Grützmann R; Hohenberger WM; Schmid A; Jacobasch L; Croner RS; Reinacher-Schick A; Hopt UT; Pirkl A; Oettle H; Fietkau R; Golcher H
BMC Cancer; 2019 Oct; 19(1):979. PubMed ID: 31640628
[TBL] [Abstract][Full Text] [Related]
6. Synoptic CT scan reporting of pancreatic adenocarcinoma to align with international consensus guidelines on surgical resectability: a Victorian pilot.
Pilgrim CHC; Maciejewska A; Ayres N; Ellis S; Goodwin M; Zalcberg JR; Haydon A
ANZ J Surg; 2022 Oct; 92(10):2565-2570. PubMed ID: 36054233
[TBL] [Abstract][Full Text] [Related]
7. Staging of pancreatic cancer: resectable, borderline resectable, and unresectable disease.
Soloff EV; Zaheer A; Meier J; Zins M; Tamm EP
Abdom Radiol (NY); 2018 Feb; 43(2):301-313. PubMed ID: 29198002
[TBL] [Abstract][Full Text] [Related]
8. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
[TBL] [Abstract][Full Text] [Related]
9. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease.
Kulkarni NM; Soloff EV; Tolat PP; Sangster GP; Fleming JB; Brook OR; Wang ZJ; Hecht EM; Zins M; Bhosale PR; Arif-Tiwari H; Mannelli L; Kambadakone AR; Tamm EP
Abdom Radiol (NY); 2020 Mar; 45(3):716-728. PubMed ID: 31748823
[TBL] [Abstract][Full Text] [Related]
10. Resectability of pancreatic adenocarcinoma in patients with locally advanced disease downstaged by preoperative therapy: a challenge for MDCT.
Morgan DE; Waggoner CN; Canon CL; Lockhart ME; Fineberg NS; Posey JA; Vickers SM
AJR Am J Roentgenol; 2010 Mar; 194(3):615-22. PubMed ID: 20173136
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Kaufmann B; Hartmann D; D'Haese JG; Stupakov P; Radenkovic D; Gloor B; Friess H
Dig Surg; 2019; 36(6):455-461. PubMed ID: 30408790
[TBL] [Abstract][Full Text] [Related]
12. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.
Ei S; Takahashi S; Ogasawara T; Mashiko T; Masuoka Y; Nakagohri T
Gut Liver; 2023 Sep; 17(5):698-710. PubMed ID: 36843421
[TBL] [Abstract][Full Text] [Related]
14. Imaging Assessment of Pancreatic Cancer Resectability After Neoadjuvant Therapy:
Soloff EV; Al-Hawary MM; Desser TS; Fishman EK; Minter RM; Zins M
AJR Am J Roentgenol; 2022 Apr; 218(4):570-581. PubMed ID: 34851713
[TBL] [Abstract][Full Text] [Related]
15. Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic performance of NCCN criteria for resection vs CT-determined resectability.
Jang JK; Choi SJ; Byun JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Hwang DW; Kim SC
J Hepatobiliary Pancreat Sci; 2022 Sep; 29(9):1025-1034. PubMed ID: 35658103
[TBL] [Abstract][Full Text] [Related]
16. Vascular involvement and resectability of pancreatic ductal adenocarcinoma on contrast-enhanced MRI: comparison with pancreatic protocol CT.
Noda Y; Kawai N; Kaga T; Ishihara T; Hyodo F; Kato H; Kambadakone AR; Matsuo M
Abdom Radiol (NY); 2022 Aug; 47(8):2835-2844. PubMed ID: 35760922
[TBL] [Abstract][Full Text] [Related]
17. CT in the prediction of margin-negative resection in pancreatic cancer following neoadjuvant treatment: a systematic review and meta-analysis.
Park S; Jang JK; Byun JH; Kim JH; Lee SS; Kim HJ; Hong SB; Park SH
Eur Radiol; 2021 May; 31(5):3383-3393. PubMed ID: 33123793
[TBL] [Abstract][Full Text] [Related]
18. Applicability of current NCCN Guidelines for pancreatic adenocarcinoma resectability: analysis and pitfalls.
Garces-Descovich A; Beker K; Jaramillo-Cardoso A; James Moser A; Mortele KJ
Abdom Radiol (NY); 2018 Feb; 43(2):314-322. PubMed ID: 29392370
[TBL] [Abstract][Full Text] [Related]
19. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
Jang JK; Byun JH; Kang JH; Son JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Kim SC; Lee MG
Eur Radiol; 2021 Feb; 31(2):813-823. PubMed ID: 32845389
[TBL] [Abstract][Full Text] [Related]
20. The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma.
Sakaguchi T; Satoi S; Yamamoto T; Yamaki S; Sekimoto M
Surg Today; 2020 Apr; 50(4):335-343. PubMed ID: 31993761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]